This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Early this year, investigators working with the Cochrane Collaboration published an update on the use of neuraminidase inhibitors (oseltamivir and zanamivir) for the prevention and treatment of influenza in healthy individuals.1 This updated version expands on a 2009 Cochrane review2 that reported inconclusive findings regarding the effectiveness of oseltamivir, mainly due to missing data from prior, unpublished studies. The drug manufacturer had offered to supply the missing information, but reportedly failed to do so. So, the investigators obtained regulatory review information, consisting of thousands of pages of individual patient results from clinical trials, via a Freedom of Information Act request. They sought to reconcile any data discrepancies with …
Individual Login
Institutional Login
You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.
Log in through your institution
Purchase access
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.